Endo International Adds Board Members
The global specialty pharma company Endo International PLC has appointed Douglas S. Ingram and Todd B. Sisitsky to its board of directors. Ingram brings 20 years of biotech and pharma experience to the business, and is currently the CEO of Chase Pharmaceuticals Corporation. He was previously president of Allergan Inc., a role which he left last March. Sisitsky is the managing partner of TPC Capital and a member of the TPB executive committee, co-leading the firm’s investment activities in the healthcare services and pharma/medical device sectors.
You may also be interested in...
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.